Literature DB >> 21477419

Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome.

S E Reme1, D Stahl, T Kennedy, R Jones, S Darnley, T Chalder.   

Abstract

BACKGROUND: Cognitive behaviour therapies (CBTs) have through several trials been demonstrated to reduce symptoms and disability in irritable bowel syndrome (IBS) patients, but the mechanisms responsible for the changes are still unknown. The aim of this study was to test a theoretical model of CBT and investigate if cognitions and/or behaviour mediated the changes seen in CBT for IBS.
METHOD: To assess for possible mediating effects, we applied path analysis to the dataset of 149 diagnosed participants randomized to mebeverine hydrochloride plus CBT or mebeverine hydrochloride alone. Primary outcome was symptom severity, while secondary outcomes were work and social adjustment and anxiety.
RESULTS: The path analyses supported mediational paths for all outcomes. Changes in behaviour and cognitions mediated all three outcomes, with models placing behaviour change 'upstream' of cognition change having best fit. The analyses of model fits revealed best fit for the anxiety model and hence provide increased confidence in the causal model of anxiety.
CONCLUSIONS: Changes in behaviour and cognitions mediate the change in CBT given to IBS patients. The results strengthen the validity of a theoretical model of CBT by confirming the interaction of cognitive, emotional and behavioural factors in IBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21477419     DOI: 10.1017/S0033291711000328

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  11 in total

1.  Persistence of gastrointestinal symptoms in irritable bowel syndrome and ulcerative colitis: study protocol for a three-arm randomised controlled trial (SOMA.GUT-RCT).

Authors:  Bernd Löwe; Yvonne Nestoriuc; Viola Andresen; Eik Vettorazzi; Antonia Zapf; Sina Hübener; Kerstin Maehder; Luisa Peters; Ansgar W Lohse
Journal:  BMJ Open       Date:  2022-06-14       Impact factor: 3.006

Review 2.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model.

Authors:  Miranda A L van Tilburg; Olafur S Palsson; William E Whitehead
Journal:  J Psychosom Res       Date:  2013-04-09       Impact factor: 3.006

Review 4.  Cognitive behavioral approach to understanding irritable bowel syndrome.

Authors:  Goran Hauser; Sanda Pletikosic; Mladenka Tkalcic
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 5.  Cognitive-behavioral therapy for the management of irritable bowel syndrome.

Authors:  Qing-Lin Tang; Guo-Yao Lin; Ming-Qing Zhang
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

6.  Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial.

Authors:  Brjánn Ljótsson; Gerhard Andersson; Erik Andersson; Erik Hedman; Perjohan Lindfors; Sergej Andréewitch; Christian Rück; Nils Lindefors
Journal:  BMC Gastroenterol       Date:  2011-10-12       Impact factor: 3.067

7.  Persistent physical symptoms reduction intervention: a system change and evaluation (PRINCE)-integrated GP care for persistent physical symptoms: protocol for a feasibility and cluster randomised waiting list, controlled trial.

Authors:  Meenal Patel; Kirsty James; Rona Moss-Morris; Mujtaba Husain; Mark Ashworth; Philipp Frank; Nicola Ferreira; Iris Mosweu; Paul McCrone; Matthew Hotopf; Anthony David; Sabine Landau; Trudie Chalder
Journal:  BMJ Open       Date:  2019-07-23       Impact factor: 2.692

8.  Persistent physical symptoms reduction intervention: a system change and evaluation in secondary care (PRINCE secondary) - a CBT-based transdiagnostic approach: study protocol for a randomised controlled trial.

Authors:  Trudie Chalder; Meenal Patel; Kirsty James; Matthew Hotopf; Philipp Frank; Katie Watts; Paul McCrone; Anthony David; Mark Ashworth; Mujtaba Husain; Toby Garrood; Rona Moss-Morris; Sabine Landau
Journal:  BMC Psychiatry       Date:  2019-10-22       Impact factor: 3.630

9.  A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Sahar M El-Haggar; Sahar K Hegazy; Sherief M Abd-Elsalam; Eslam B Elkaeed; Ahmed A Al-Karmalawy; Mostafa M Bahaa
Journal:  J Inflamm Res       Date:  2022-02-19

10.  Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.

Authors:  Jeffrey M Lackner; James Jaccard
Journal:  J Consult Clin Psychol       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.